NIACIN ER (niacin)
NIACIN/NIACINAMIDE (VITAMIN B-3) · HYPERCHOLESTEROLEMIA ·+6
CHARTWELL RX LL
Drug class
Antihyperlipidemics - Nicotinic Acid and Derivatives
Antihyperlipidemics – Nicotinic Acid and Derivatives constitutes a recognized therapeutic class of lipid-modifying agents that includes nicotinic acid (niacin) and related chemical analogues such as acipimox. Read more about Antihyperlipidemics - Nicotinic Acid and Derivatives
12 drugs in this class 12 manufacturers
Drugs in Antihyperlipidemics - Nicotinic Acid and Derivatives
NIACIN
NIACIN/NIACINAMIDE (VITAMIN B-3) · HYPERCHOLESTEROLEMIA ·+6
REDMONT PHARMAC
NIACIN ER (niacin)
NIACIN/NIACINAMIDE (VITAMIN B-3) · HYPERCHOLESTEROLEMIA ·+6
Lannett Company
Filter & compare in the drug finder →
Opens the drug finder with Antihyperlipidemics - Nicotinic Acid and Derivatives preselected. Add indication or manufacturer filters there.
Antihyperlipidemics – Nicotinic Acid and Derivatives constitutes a recognized therapeutic class of lipid-modifying agents that includes nicotinic acid (niacin) and related chemical analogues such as acipimox.
At pharmacological doses, these agents primarily act by activating hydroxycarboxylic acid receptor 2 (HCA2/GPR109A) in adipose tissue to inhibit lipolysis, thereby decreasing circulating free fatty acid flux to the liver, attenuating hepatic synthesis of very-low-density lipoproteins and triglycerides, and raising high-density lipoprotein cholesterol.
Clinically, this drug class is primarily used as an adjunct to diet in the management of dyslipidemia, mixed dyslipidemia, and severe hypertriglyceridemia, as well as to lower cardiovascular risk in selected patient populations.
-
nih.gov
Antihyperlipidemics – Nicotinic Acid and Derivatives constitutes a recognized therapeutic class of lipid-modifying agents that includes nicotinic acid (niacin) and related chemical analogues such as acipimox
-
europa.eu
Antihyperlipidemics – Nicotinic Acid and Derivatives constitutes a recognized therapeutic class of lipid-modifying agents that includes nicotinic acid (niacin) and related chemical analogues such as acipimox
-
nih.gov
At pharmacological doses, these agents primarily act by activating hydroxycarboxylic acid receptor 2 (HCA2/GPR109A) in adipose tissue to inhibit lipolysis, thereby decreasing circulating free fatty acid flux to the liver, attenuating hepatic synthesis of very-low-density lipoproteins and triglycerides, and raising high-density lipoprotein cholesterol
-
nih.gov
At pharmacological doses, these agents primarily act by activating hydroxycarboxylic acid receptor 2 (HCA2/GPR109A) in adipose tissue to inhibit lipolysis, thereby decreasing circulating free fatty acid flux to the liver, attenuating hepatic synthesis of very-low-density lipoproteins and triglycerides, and raising high-density lipoprotein cholesterol
-
durgical.com
At pharmacological doses, these agents primarily act by activating hydroxycarboxylic acid receptor 2 (HCA2/GPR109A) in adipose tissue to inhibit lipolysis, thereby decreasing circulating free fatty acid flux to the liver, attenuating hepatic synthesis of very-low-density lipoproteins and triglycerides, and raising high-density lipoprotein cholesterol Clinically, this drug class is primarily used as an adjunct to diet in the management of dyslipidemia, mixed dyslipidemia, and severe hypertriglyce...
-
acpjournals.org
Clinically, this drug class is primarily used as an adjunct to diet in the management of dyslipidemia, mixed dyslipidemia, and severe hypertriglyceridemia, as well as to lower cardiovascular risk in selected patient populations
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.